Bioequivalence Evaluation of Two Telmisartan Tablets in Healthy Volunteers
Dong-Xiang Zeng, Ren Huayi, Kunyan Li, Lizhi Cao, Song Jian-ping
Abstract
Dong-Xiang Zeng, Ren Huayi, Kunyan Li, Lizhi Cao, Song Jian-ping
Abstract
目的:研究国产(受试制剂)与进口(参比制剂)替米沙坦片的人体生物等效性.方法:采用LC-MS法,测定18名健康男性单次交叉口服参比制剂及受试制剂80 mg后血浆中不同时间点的药物浓度,计算其药动学参数和相对生物利用度.结果:受试制剂及参比制剂的主要药物动力学参数Cmax分别为(428.8±108.6)和(420.7±93.0)ng·h-1·ml-1;tmax分别为(1.0±0.3)和(1.3±0.5)h;AUC0-96分别为(3 041.8±409.4)和(3 144.1±260.4)ng·h-1·ml-1.受试制剂相对生物利用度为96.8%±10.6%.结论:受试制剂与参比制剂具有生物等效性.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
目的:研究国产(受试制剂)与进口(参比制剂)替米沙坦片的人体生物等效性.方法:采用LC-MS法,测定18名健康男性单次交叉口服参比制剂及受试制剂80 mg后血浆中不同时间点的药物浓度,计算其药动学参数和相对生物利用度.结果:受试制剂及参比制剂的主要药物动力学参数Cmax分别为(428.8±108.6)和(420.7±93.0)ng·h-1·ml-1;tmax分别为(1.0±0.3)和(1.3±0.5)h;AUC0-96分别为(3 041.8±409.4)和(3 144.1±260.4)ng·h-1·ml-1.受试制剂相对生物利用度为96.8%±10.6%.结论:受试制剂与参比制剂具有生物等效性.
Key concepts: Bioequivalence, Telmisartan, Medicine, Pharmacology, Pharmacokinetics, Internal medicine, Blood pressure